Hutchison China Meditech has commenced a Phase IIb/III study comparing surufatinib with capecitabine in patients with advanced biliary tract cancer (BTC), whose disease progressed to first-line chemotherapy.
The study investigates the effects of surufatinib against the chemotherapy agent capecitabine as a second-line therapy in patients with unresectable or metastatic BTC. The study complements a China based Phase Ib/II proof-of-concept study for surufatinib in BTC, in addition to a Phase Ib study in the US enrolling patients with BTC and pancreatic neuroendocrine tumours (NET).
This is in addition to the company’s already approved drug Fruquintinib, branded Elunate in China, which received approval in China for third line patients late last year. Fruquintinib is a highly selective tyrosine kinase inhibitor meant to block cancer growth.